KLHL25: A Protein with Multiple Talents for Disease Treatment and Research

Target Name: KLHL25

NCBI ID: G64410

KLHL25

KLHL25: A Protein with Multiple Talents for Disease Treatment and Research

KLHL25 (KLH25_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the KLH family of proteins, which are known for their role in intracellular signaling.

One of the unique aspects of KLHL25 is its ability to interact with several different signaling pathways, including the TGF-灏? pathway and the PI3K/Akt pathway. This means that KLHL25 can potentially play a role in a wide range of biological processes, including cell growth, differentiation, and survival.

In addition to its potential role in intracellular signaling, KLHL25 has also been shown to be involved in several different diseases and conditions. For example, KLHL25 has been associated with a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Despite these promising findings, much more research is needed about the role of KLHL25 in the disease process. In particular, there is a need for more research on the molecular mechanisms that govern its function and how it interacts with other proteins.

In conclusion, KLHL25 is a protein that has the potential to be a drug target or biomarker for a wide range of diseases. Its unique ability to interact with multiple signaling pathways and its association with a number of neurodegenerative diseases make it an intriguing target for further research.

Protein Name: Kelch Like Family Member 25

Functions: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex involved in various processes, such as translation homeostasis and lipid synthesis (PubMed:22578813, PubMed:27664236, PubMed:34491895). The BCR(KLHL25) ubiquitin ligase complex acts by mediating ubiquitination of hypophosphorylated EIF4EBP1 (4E-BP1): ubiquitination and subsequent degradation of hypophosphorylated EIF4EBP1 (4E-BP1) probably serves as a homeostatic mechanism to maintain translation and prevent eIF4E inhibition when eIF4E levels are low (PubMed:22578813). The BCR(KLHL25) complex does not target EIF4EBP1 (4E-BP1) when it is hyperphosphorylated or associated with eIF4E (PubMed:22578813). The BCR(KLHL25) complex also acts as a regulator of lipid synthesis by mediating ubiquitination and degradation of ACLY, thereby inhibiting lipid synthesis (PubMed:27664236, PubMed:34491895). BCR(KLHL25)-mediated degradation of ACLY promotes fatty acid oxidation and is required for differentiation of inducible regulatory T (iTreg) cells (PubMed:34491895)

The "KLHL25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHL25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets